$200,000 (2 years)
Previous work on a major synaptic protein, Calcium/calmodulin-dependent protein Kinase II (CaMKII), suggests that it has a central role in producing the developmental deficits in Angelman syndrome (AS). This research seeks to better understand how CaMKII activity is mediated by a group of regulatory proteins known as phosphatases. AS treatment strategies involving CaMKII activation via phosphatase-catalyzed dephosphorylation may result from such studies.
The mission of Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.